CGEM

15.98

0.38% 0.06

Dopo l'orario di chiusura: 15.98

Cullinan Therapeutics Inc (CGEM)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Forum Previsione

Precedente Chiudi:

$15.92

Aprire:

$15.84

Volume 24 ore:

363.44K

Relative Volume:

0.70

Capitalizzazione di mercato:

$926.47M

Reddito:

Utile/perdita netta:

$-153.16M

Rapporto P/E:

-4.7418

EPS:

-3.37

Flusso di cassa netto:

$-134.48M

1 W Prestazione:

-5.56%

1M Prestazione:

-2.20%

6M Prestazione:

-43.63%

1 anno Prestazione:

+61.09%

Intervallo 1D:

$15.15

$16.00

Intervallo di 1 settimana:

$15.15

$16.79

Portata 52W:

$7.64

$30.19

Cullinan Therapeutics Inc Stock (CGEM) Company Profile

Nome

Cullinan Therapeutics Inc

Settore

Healthcare (1182)

Industria

Biotechnology (671)

Telefono

617-410-4650

Indirizzo

ONE MAIN STREET, CAMBRIDGE

Dipendente

Cinguettio

Prossima data di guadagno

2024-11-06

Ultimi documenti SEC

CGEM's Discussions on Twitter

Cullinan Therapeutics Inc Stock (CGEM) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2024-05-01	Iniziato	Stifel	Buy
2024-04-15	Iniziato	William Blair	Outperform
2024-02-15	Iniziato	Wedbush	Outperform
2023-06-15	Iniziato	TD Cowen	Outperform
2022-11-21	Iniziato	BTIG Research	Buy
2021-04-27	Aggiornamento	Morgan Stanley	Equal-Weight → Overweight
2021-02-02	Iniziato	Evercore ISI	Outperform
2021-02-02	Iniziato	Morgan Stanley	Equal-Weight
2021-02-02	Iniziato	SVB Leerink	Outperform
2021-02-01	Iniziato	H.C. Wainwright	Buy

Mostra tutto

Cullinan Therapeutics Inc Borsa (CGEM) Ultime notizie

07:16 AM

Cullinan Therapeutics to Participate in Fireside Chat at Stifel 2024 Healthcare Conference - StockTitan

07:16 AM

02:11 AM

Vanguard Group Inc's Strategic Acquisition in Cullinan Therapeutics Inc - GuruFocus.com

02:11 AM

Nov 04, 2024

Cullinan Therapeutics to Present Preclinical Data for - GlobeNewswire

Nov 04, 2024

Cullinan Therapeutics to Present Preclinical Data for CLN-978, a CD19-directed T Cell Engager, at ACR Convergence 2024 - StockTitan

Nov 04, 2024

Nov 03, 2024

Analysts Set Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Target Price at $31.67 - MarketBeat

Nov 03, 2024

Oct 30, 2024

FY2027 Earnings Forecast for CGEM Issued By Leerink Partnrs - MarketBeat

Oct 30, 2024

Oct 24, 2024

Cullinan Therapeutics (NASDAQ:CGEM) Receives New Coverage from Analysts at UBS Group - MarketBeat

Oct 24, 2024

Oct 22, 2024

Exchange Traded Concepts LLC Sells 2,961 Shares of Cullinan Therapeutics, Inc. (NASDAQ:CGEM) - Defense World

Oct 22, 2024

SG Americas Securities LLC Sells 70,115 Shares of Cullinan Therapeutics, Inc. (NASDAQ:CGEM) - MarketBeat

Oct 22, 2024

Oct 20, 2024

cullinan oncology, inc. Earnings dates - RTTNews

Oct 20, 2024

Oct 18, 2024

Cullinan Therapeutics (NASDAQ:CGEM) Stock Price Down 3.2%Here's Why - MarketBeat

Oct 18, 2024

Oct 17, 2024

Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Short Interest Update - MarketBeat

Oct 17, 2024

Cullinan Oncology stock gets 5% price target increase, H.C. Wainwright remains bullish after FDA approval - Investing.com

Oct 17, 2024

Oct 16, 2024

Cullinan Therapeutics (NASDAQ:CGEM) Trading Up 7%Here's Why - MarketBeat

Oct 16, 2024

Cullinan Therapeutics' (CGEM) "Buy" Rating Reiterated at HC Wainwright - MarketBeat

Oct 16, 2024

Cullinan Therapeutics Gets FDA Approval for Lupus Treatment Study - Marketscreener.com

Oct 16, 2024

Cullinan Therapeutics Receives U.S. FDA Clearance of - GlobeNewswire

Oct 16, 2024

Cullinan Therapeutics Receives U.S. FDA Clearance of Investigational New Drug Application for CLN-978 Administered Subcutaneously in Patients with Moderate to Severe Systemic Lupus Erythematosus - StockTitan

Oct 16, 2024

Oct 11, 2024

How did Cullinan Therapeutics Inc (CGEM) fare last session? - US Post News

Oct 11, 2024